Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2, 2018. The report serves as a notification of a specific corporate governance event regarding director shareholdings and executive appointments.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of personnel changes and does not contain financial statements or performance data.
Material Changes
The primary material change disclosed is the assumption of a new executive role by Dr. Hal Barron. Effective January 1, 2018, Dr. Barron assumed the positions of Chief Scientific Officer, President of R&D, and Executive Director, following an announcement made on November 8, 2017.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document is limited to confirming the appointment date and the shareholding status of the new executive.
Important Facts for Investors
- Dr. Hal Barron officially began his role as Chief Scientific Officer and President, R&D, on January 1, 2018.
- As of his appointment to the Board, Dr. Barron held 1,644 American Depositary Shares in the Company.
- This filing does not include financial results or operational metrics for the period.